Australia Move To Extend Shelf Life Of Tamiflu Draws Opposition
This article was originally published in PharmAsia News
Australia's decision to allow drug makers to sell expired doses of antivirals such as Roche's Tamiflu (oseltamivir) during the H1N1 flu crisis is drawing political opposition. With supplies of flu antivirals dwindling in Australia, the Therapeutic Goods Administration approved the extension of the shelf-life of Tamiflu after being assured by Roche the drug is safe and effective for two years longer the expiration date indicates. But the opposition party in Parliament noted the drugs already had been returned to Roche and said the government would end up paying for them twice if it now buys back the expired doses. (Click here for more
You may also be interested in...
Mooted some time ago, the Medicare Part D Drug Rebate Rule and the Medicare Part B Most-Favored-Nation Model have now been finalized by US President Donald Trump. But US off-patent body the Association for Accessible Medicines feels “further action is necessary.”
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.